Amanda F. Austin

Experience

Licensing and Collaborations; Commercial Arrangements

• Pfizer Inc. in a $1.24 billion dollar ex-U.S. strategic collaboration agreement with Biohaven Pharmaceutical Company to commercialize rimegepant, a therapy approved in the U.S. as Nurtec ODT for the acute treatment of migraine attacks and the preventative treatment of episodic migraines.  
• A global biopharmaceutical company in its collaboration, option and license agreement with a clinical stage biotechnology company to research and develop a vaccine-based immunotherapy for human immunodeficiency virus (HIV) infection.
• A global biopharmaceutical company on a number of transactions, including a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against certain oncology and immunology targets and an exclusive worldwide option and license agreement for a costimulation antagonist for autoimmune and inflammatory diseases.
• Provention Bio in a strategic collaboration with a subsidiary of Huadong Medicine to develop and commercialize PRV-3279, a bispecific antibody-based molecule in China.
• Ginkgo Bioworks in a number of transactions, including a strategic partnership with Aldevron to optimize production of vaccinia capping enzymes (VCE), and a partnership with Berkeley Lights to use BLI's optofluidic platform in Ginkgo's genetic engineering foundries.
• Paratek Pharmaceuticals, including in its license agreement with Almirall for the development and commercialization of SEYSARA® in the US and China.
• Beam Therapeutics in connection with its licenses from Editas Medicine and the Broad Institute.
• Ironwood Pharmaceuticals in its commercial licensing agreement with AstraZeneca for the U.S. rights to Zurampic, an FDA-approved treatment for hyperuricemia.
• A leading global biotechnology company in a $300 million joint venture to develop and market biosimilars with a Korea-based company.
• Multiple clients, including a nonprofit institution and a leading pharmaceutical company, with the development of licensing templates for internal use.

IP/Licensing Structuring in Asset Contributions/Divestitures

• Asklepios BioPharmaceutical (AskBio), a biopharmaceutical gene therapy company, in its acquisition by Bayer AG.
• Pfizer, including in its acquisition of Trillium Therapeutics, its contribution of assets related to allogeneic chimeric antigen receptor T cell (CAR-T) therapy to Allogene Therapeutics, and in Pfizer’s option to acquire AM-Pharma, a private company focused on the development of recombinant human Alkaline Phosphatase (recAP) for the treatment of inflammatory diseases.
• Gilead Sciences, including in its exclusive option to acquire Pionyr Immunotherapeutics Inc. and its exclusive option to acquire Tizona Therapeutics, Inc.
• Becton Dickinson in a number of transactions, including its acquisition of Cubex and its divestiture of its advanced bioprocessing business to ThermoFisher.
• A public university in the sale of a portion of its royalty interest in an orphan drug.